Sanofi获得中国两项药物批准:Qfitlia用于预防血友病,Cablivi用于罕见的血凝结障碍。 Sanofi gains two Chinese drug approvals: Qfitlia for hemophilia prevention and Cablivi for a rare blood clotting disorder.

中国的药物监管者已经批准Sanofi的Qfitlia用于血友病和Cablivi用于罕见的血凝胶紊乱,这标志着该公司今年在中国的第五次药物批准。 China’s drug regulator has approved Sanofi’s Qfitlia for hemophilia and Cablivi for a rare blood clotting disorder, marking the company’s fifth drug approval in the country this year. Qfitlia是一种抗血清素低位疗法,是首次对血友病患者进行常规预防,而Cablivi是一种以纳米体为基础的治疗,其对象是成人和青少年的免疫媒介血清血清血清血清疏松。 Qfitlia, an antithrombin-lowering therapy, is the first for routine prevention in hemophilia patients, while Cablivi, a Nanobody-based treatment, targets immune-mediated thrombotic thrombocytopenic purpura in adults and adolescents. 这些批准扩大了Sanofi在中国的罕见疾病组合,解决了严重未满足的医疗需求。 The approvals expand Sanofi’s rare disease portfolio in China, addressing serious unmet medical needs.